Myeloid neoplasm
MONDO:0005170Proliferation of myeloid cells originating from a primitive stem cell.
Also known as: myeloid malignancy, myeloid neoplasm, myeloid tumor, myeloid tumour
4465 clinical trials for this condition and its sub-types, 48 tagged with Myeloid neoplasm itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Myeloid neoplasm
-
Myeloproliferative neoplasm 166 trials · 1,632 incl. sub-types
13 sub-types
- Myeloid leukemia 30 trials · 1,334 incl. sub-types Sub-types →
- Myelodysplastic/myeloproliferative neoplasm 81 trials · 234 incl. sub-types Sub-types →
- Primary myelofibrosis 191 trials · 195 incl. sub-types Sub-types →
- Myelofibrosis 149 trials
- Erythroid neoplasm 0 trials · 95 incl. sub-types Sub-types →
- Essential thrombocythemia 67 trials
- Therapy-related myeloid neoplasm 54 trials
- Myeloproliferative neoplasm, unclassifiable 11 trials · 16 incl. sub-types Sub-types →
- Transient myeloproliferative syndrome 13 trials
- Chronic neutrophilic leukemia 10 trials
- Chronic eosinophilic leukemia 9 trials
- Myeloproliferative disease, autosomal recessive 0 trials
- Thrombocytopenia 6 0 trials
-
Plasma cell myeloma 1,108 trials · 1,131 incl. sub-types
3 sub-types
- Smoldering plasma cell myeloma 63 trials · 64 incl. sub-types Sub-types →
- Non-secretory plasma cell myeloma 1 trial
- Osteosclerotic plasma cell myeloma 0 trials
-
Mast cell neoplasm 0 trials · 34 incl. sub-types
2 sub-types
- Mastocytosis 15 trials · 34 incl. sub-types Sub-types →
- Mastocytoma 0 trials Sub-types →
-
CD4+/CD56+ hematodermic neoplasm 31 trials
Most studied deeper sub-types
-
New drug DFV890 takes on Hard-to-Treat blood cancers
Disease control OngoingThis early-stage trial tests a new drug called DFV890 in about 62 adults with low-risk myelodysplastic syndromes, low-risk chronic myelomonocytic leukemia, or high-risk clonal cytopenia of undetermined significance. The main goals are to check the drug's safety, find the best dos…
Phase 1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New drug combo aims to stop blood cancer relapse after transplant in kids
Disease control OngoingThis study tests whether giving two drugs, decitabine and filgrastim, after a stem cell transplant can help prevent blood cancers like AML and MDS from coming back in children and young adults. About 37 participants will receive the drug combination for up to 6 cycles. The main g…
Phase 2 • Sponsor: Franziska Wachter • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
New drug cocktail shows promise for Hard-to-Treat leukemia
Disease control OngoingThis early-phase trial tests a combination of three drugs—azacitidine, venetoclax, and pevonedistat—in adults newly diagnosed with a challenging form of acute myeloid leukemia (AML). The goal is to find the best dose and see if the combo can improve remission rates. About 40 part…
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Experimental chemo combo aims to help kids with rare secondary blood cancers
Disease control OngoingThis study tests a chemotherapy drug called CPX-351 (Vyxeos) in 25 patients under 22 years old who have secondary myeloid neoplasms, a type of blood cancer that develops after previous cancer treatment. Participants receive one or two rounds of CPX-351, followed by a stem cell tr…
Phase 2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug MP0533 takes aim at Hard-to-Treat leukemia
Disease control OngoingThis early-stage trial tests a new drug called MP0533 in adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back or not responded to treatment. The drug is designed to help the body's immune cells find and attack cancer cells. The study will …
Phase 1/2 • Sponsor: Molecular Partners AG • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Immune cell booster for leukemia patients pulled before start
Disease control CancelledThis study aimed to see if giving special immune cells (γδ T cells) after a stem cell transplant could help prevent leukemia from coming back in high-risk patients. It was planned for adults aged 18-65 with acute myeloid leukemia. However, the study was withdrawn before any parti…
Early phase 1 • Sponsor: Guangzhou Bio-gene Technology Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
Cancer drug shows promise in taming rare blood disorder
Disease control OngoingThis study tests whether the drug imatinib (Gleevec) can safely lower high levels of eosinophils (a type of white blood cell) in people with hypereosinophilic syndrome (HES), a rare condition that can damage organs. About 70 adults and children (age 2 and up) with a specific form…
Phase 2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New Triple-Drug cocktail targets tough blood cancers
Disease control OngoingThis early-phase study tests the safety of combining three drugs—navitoclax, venetoclax, and decitabine—for people with advanced myeloid blood cancers like leukemia and myelofibrosis. The goal is to find a safe dose that can control the disease. Sixteen adults aged 18 and older a…
Phase 1 • Sponsor: Jacqueline Garcia, MD • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC